In addition, other neurodegenerative diseases especially linked to synucleinopathies and protein aggregation in which the therapeutic implications of HSP90 inhibitors have been suggested, may perhaps consider UBA52 as a promising candidate for targeting disease therapeutics and mitigating neuronal death. This evidence concerns the gene UBA52 and synucleinopathy.